Compass Therapeutics Incis A Clinical Stage Biopharmaceutical Company Based In Bostonmassachusettsfounded In 2014The Company Specializes In Developing Antibody Based Therapeutics Aimed At Treating Oncology And Autoimmune Diseaseswith A Team Of Around 35 Employees Led By Ceo Thomas Schuetzcompass Utilizes Proprietary Platforms Like Stitchmabsa C And Common Light Chain Technology To Create Bispecific Antibodies The Company S Pipeline Includes Several Promising Candidatestovecimig Is A Bispecific Antibody That Targets Dll4 And Vegf A Pathways To Inhibit Tumor Angiogenesisctx 471 Is A Cd137 Agonist Monoclonal Antibody Designed To Enhance Anti Tumor Immune Responsesother Notable Candidates Include Ctx 8371Which Targets Pd 1 And Pd L1 Pathwaysand Ctx 10726A Dual Targeting Antibody Against Pd 1 And Vegf Acompass Focuses On Combination Therapiesadvancing Their Candidates As Standalone Treatments Or In Synergistic Pairings To Address Both Innate And Adaptive Immune System Components
